Skip to main content

Table 1 Baseline demographic and clinical characteristics in the overall study population; in the central retinal vein occlusion (CRVO) and branch retinal vein occlusion (BRVO) samples; and in the treatment naïve and previously treated patients

From: Optical coherence tomography biomarkers in patients with macular edema secondary to retinal vein occlusion treated with dexamethasone implant

Variable Overall (n = 57) CRVO (n = 15) BRVO (n = 42) P* Naïve (n = 31) Previously treated (n = 26) P*
Type of RVO, n (%)
 CRVO 15 (26.3) N.A. N.A. N.A. 9 (21.0) 6 (23.1) 0.7647
 BRVO 42 (73.7) 22 (71.0) 20 (76.9)
Treatment status, n (%)
 Naïve 31 (54.4) 9 (60.0) 22 (52.4) 0.7647a N.A. N.A. N.A.
 Previously treated 26 (45.6) 6 (40.0) 20 (47.6)
Age, years
 Mean (SD) 72.4 (9.3) 70.6 (9.1) 73.0 (9.4) 0.3994 72.3 (10.5) 72.5 (7.9) 0.8225
 95% CI 69.9 to 74.9 65.6 to 75.7 70.1 to 76.0 68.4 to 76.1 69.3 to 75.7
Sex, n (%)
 Women 34 (59.6) 10 (66.7) 24 (57.1) 0.5224 19 (61.3) 15 (57.7) 0.7846
 Men 23 (40.4) 5 (33.3) 18 (42.9) 12 (38.7) 11 (42.3)
Eye, n (%)
 Right 25 (43.9) 5 (33.3 20 (47.6) 0.3428 14 (45.2) 11 (42.3) 0.8303
 Left 32 (56.1) 10 (66.7) 22 (52.4) 17 (54.8) 15 (57.7)
NOII
 Mean (SD) 1.3 (1.7) 1.1 (1.5) 1.4 (1.8) 0.5850 0.0 2.9 (1.4) < 0.0001
 95% CI 0.8 to 1.8 0.2 to 1.9 0.8 to 1.9 0.0 to 0.0 2.3 to 3.4
Type of RVO-ME, n (%)
 SLRS 2 (3.5) 1 (6.7) 1 (2.4) 0.3056b 2 (6.5) 0 (0.0) 0.1474b
 CME 20 (35.1) 3 (20.0) 17 (40.5) 6 (19.4) 14 (53.8)
 SRD 35 (61.4) 11 (73.3) 24 (57.1) 23 (74.2) 12 (46.2)
Duration of RVO-ME, days
 Mean (SD) 61.3 (81.6) 60.7 (70.8) 61.5 (85.9) 0.8632 62.5 (94.3) 59.9 (65.2) 0.5424
 95% CI 39.7 to 83.0 21.5 to 99.9 34.8 to 84.3 27.9 to 97.1 33.6 to 86.2
BCVA**
 Mean (SD) 55.2 (19.4) 55.5 (15.7) 55.1 (20.7) 0.6738 55.0 (19.0) 55.5 (20.3) 0.7524
 95% CI 50.1 to 60.4 46.8 to 64.2 48.7 to 61.6 48.1 to 62.0 47.3 to 63.7  
CRT, μm
 Mean (SD) 567.6 (226.2) 549.8 (158.7) 573.9 (247.3) 0.8420 617.7 (280.0) 507.9 (117.1) 0.2846
 95% CI 507.6 to627.6 461.9 to 637.7 496.9 to 651.0 515.0 to 720.4 460.6 to 555.1
NMCST500, μm
 Mean (SD) 175.1 (53.6) 180.2 (53.0) 173.7 (54.3) 0.6570 180.2 (54.6) 169.1 (52.8) 0.3610
 95% CI 160.9 to 189.4 150.9 to 209.5 156.4 to 190.3 160.2 to 200.2 147.8 to 190.4
NMCST1500, μm
 Mean (SD) 180.6 (58.4) 188.3 (60.6) 177.9 (78.1) 0.5742 183.5 (58.9) 177.2 (58.7) 0.5859
 95% CI 165.1 to 196.1 154.7 to 221.8 159.8 to 196.0 161.9 to 205.1 153.5 to 200.9
TMCST500, μm
 Mean (SD) 189.6 (76.5) 205.5 (118.5) 183.9 (55.4) 0.9278 186.4 (65.5) 193.5 (89.1) 0.6137
 95% CI 169.3 to 209.9 139.8 to 275.1 166.7 to 201.2 162.3 to 210.4 157.5 to 229.4
TMCST1500, μm
 Mean (SD) 184.1 (56.5) 194.1 (75.7) 180.5 (48.4) 0.5804 189.2 (61.4) 178.0 (50.4) 0.2866
 95% CI 169.1 to 199.1 152.1 to 236.0 165.5 to 195.6 166.7 to 211.8 157.6 to 198.4
CST, μm
 Mean (SD) 184.1 (57.0) 184.1 (67.3) 184.1 (53.7) 0.9494 186.8 (54.6) 180.8 (60.6) 0.5749
 95% CI 169.0 to 199.2 146.9 to 221.4 167.3 to 200.8 166.8 to 206.9 156.3 to 205.3
HRF, n (%)
  <  10 16 (28.1) 3 (20.0) 13 (31.0) 0.3247b 8 (25.8) 8 (30.8) 0.5098b
 10–20 23 (40.4) 11 (73.3) 12 (28.6) 12 (38.7) 11 (42.3)
  > 20 18 (31.6) 1 (6.7) 17 (40.5) 11 (35.5) 7 (26.9)
DRIL, n (%)
 Yes 34 (59.6) 10 (66.7) 24 (57.1) 0.5582a 20 (64.5) 14 (53.8) 0.4323a
 No 23 (40.4) 5 (33.3) 18 (42.9)   11 (35.5) 12 (46.2)
Cysts volume, μm3
 Mean (SD) 317.9 (145.4) 285.7 (121.8) 329.7 (152.8) 0.3268 318.9 (154.6) 316.9 (137.1) 0.9084
 95% CI 279.0 to 356.9 218.2 to 353.1 281.5 to 378.0 261.2 to 376.6 261.5 to 372.2
Cysts, n (%)
  <  100 μm 2 (3.6) 1 (6.7) 1 (2.4) 0.2838b 1 (3.3) 1 (3.8) 0.4658b
 100–200 μm 12 (21.4) 5 (33.3) 7 (17.1) 8 (26.7) 4 (15.4)
  > 200 μm 42 (75.0) 9 (60.0) 33 (80.5) 21 (70.0) 21 (80.8)
ELM, n (%)
 Non-disrupted 13 (22.8) 2 (13.3) 11 (26.2) 0.2059b 5 (16.1) 8 (30.8) 0.6727b
 Partially disrupted 24 (42.1) 6 (40.0) 18 (42.9) 16 (51.6) 8 (30.8)
 Disrupted 20 (35.1) 7 (46.7) 13 (31.0) 10 (32.39 10 (38.5)
SRF, n (%)
 Yes 35 (61.4) 11 (73.3) 24 (57.1) 0.3600a 23 (74.2) 12 (46.2) 0.0548a
 No 22 (38.6) 4 (26.7) 18 (42.9) 8 (25.8) 14 (53.8)
SRF, μm
 Mean (SD) 147.1 (112.2) 103.8 (38.8) 166.9 (129.0) 0.1097 158.4 (129.6) 125.3 (67.1) 0.3943
 95% CI 108.5 to 185.6 77.8 to 129.9 112.4 to 221.4 102.3 to 214.4 82.7 to 168.0
  1. RVO Retinal vein occlusion, CRVO Central retinal vein occlusion, BRVO Branch retinal vein occlusion, NA Not applicable, SD Standard deviation, 95% CI 95% Confidence interval, NOII Number of intravitreal injections, RVO retinal vein occlusion, ME macular edema, SLRS Sponge-like retinal swelling, CME Cystoid macular edema, SRD Serous retinal detachment, CRT Central retinal thickness, NMCST Nasal mean choroidal subfoveal thickness, TMCST Temporal mean choroidal subfoveal thickness, 500 ring of 500 μm, 1500 Ring of 1500 μm, CST Choroidal subfoveal thickness, HRF Hyperreflective foci, DRIL Disorganization of retinal inner layers, ELM External limiting membrane, SRF Serous retinal fluid
  2. aFisher exact test
  3. bChi-squared from trend test
  4. *Mann-Whitney test
  5. **Letters in the Early Treatment Diabetic Retinopathy Study (ETDRS) charts